A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata Authors: Mude Hemalatha, Tarun Narang, Muthu Sendhil Kumaran, Vinod Kumar, Hitaishi Mehta, Nusrat Shafiq, Daljit Kaur, Sunil Dogra Published: 2026 ABSTRACT Background:Treatments for moderate-to-severe alopecia areata (AA) have limited efficacy. Methotrexate, a conventional immunosuppressant, has been used for AA, while Janus kinase/signal transducer and activator of transcription (JAK–STAT) inhibitors like tofacitinib have shown promising results.Objective:To compare the efficacy of tofacitinib and methotrexate in moderate-to-severe AA.Patients and Methods:Thirty-six patients aged 18–60 years with a severity of alopecia tool (SALT) score >40 were randomized to receive either tofacitinib (5–10 mg twice daily) or methotrexate (0.3–0.5 mg/kg weekly) for 6 months, followed by 3-month follow-up. Primary outcomes measured the proportion achieving a SALT score ≤20 at 6 months. Secondary outcomes included patient-reported outcome (PRO) on scalp hair assessment, dermatology life quality index (DLQI), patient health questionnaire (PHQ) scores, relapse rates, and alkaline phosphatase (ALP) activity in scalp biopsies.Results:At 6 months, 50% of tofacitinib patients achieved a SALT score ≤20 vs. 33.3% with methotrexate (P = 0.31). A ≥ 90% SALT improvement occurred in 33.3% of tofacitinib and 11.1% of methotrexate patients (P = 0.10). The tofacitinib group had greater scalp hair PRO score reductions. Both groups showed significant DLQI and PHQ improvements, with no intergroup differences. Adverse events were reported in 38.8% of tofacitinib and 33.3% of methotrexate patients (P = 1). ALP activity was inconclusive.Limitations:Small sample size, open-label design, lack of stratification, and baseline imbalances that may affect achievable improvement and comparative interpretation.Conclusion:In this pilot trial, both tofacitinib and methotrexate improved SALT score, PRO score, and psychological outcomes, but the tofacitinib group showed greater efficacy. Larger studies are warranted to confirm findings and investigate ALP activity. Introduction Alopecia areata (AA), an autoimmune disorder affecting 2% of the population and accounting for about 25% of alopecia cases, poses treatment challenges due to limited data and lack of standardized guidelines.[12] Conventional therapies include topical treatments (e.g., intralesional corticosteroids, minoxidil, anthralin) and systemic drugs (corticosteroids, methotrexate, azathioprine, cyclosporine).[3] However, these are less effective in severe cases and carry significant side effects, necessitating newer options.[45] Janus kinase/signal transducer and activator of transcription (JAK–STAT) inhibitors have emerged as promising therapies, with baricitinib, ritlecitinib, and deuruxolitinib currently being FDA approved. Tofacitinib remains widely used due to its affordability, availability, and favorable efficacy and safety profile.[678] Methotrexate, though inexpensive, has shown inconsistent results.[910] This pilot randomized trial compared oral tofacitinib and methotrexate in moderate- to-severe AA and evaluated scalp alkaline phosphatase (ALP) activity by immunohistochemistry (IHC) as a potential biomarker, considering previous reports of reduced activity in early AA and increased activity in later stages.[11] Patients and Methods Study design and population This prospective, randomized, open-label pilot study was conducted from July 2023 to December 2024 at PGIMER, Chandigarh, following approval from the Intramural Institutional Ethics Committee, PGIMER, Chandigarh (IEC-INT/2023/MD-998) and Clinical Trials Registry registration (CTRI/2023/06/054423). Patients aged between 18 and 60 years with moderate-to-severe AA (severity of alopecia tool (SALT) score >40) and disease duration >6 months were included after obtaining informed consent . Pregnant or lactating women, and patients with significant systemic diseases, malignancies, bone marrow suppression, thromboembolic events, recent topical treatment (within 15 days), or systemic therapy in the past month were excluded. Randomization and blinding Computer-generated permuted block randomization with centralized allocation concealment was used. Sixty patients were screened, and 36 eligible patients were randomized in a 1:1 ratio to tofacitinib group (Group A) or methotrexate group (Group B), with 18 patients in each group [Supplementary Figure 1]. Treatment was administered for 6 months, followed by a 3-month tapering phase to monitor relapse. Outcome assessment was performed by a blinded investigator. Intervention Group A received oral tofacitinib 5 mg twice daily, escalated to 10 mg twice daily after 2 months in the absence of response, based on prior evidence of response within 8–12 weeks. The patients were treated at this dose for a total of 6 months, followed by tapering of 5 mg/month over 3 months.[1213] Group B received oral methotrexate 0.3 mg/kg/week, increased to 0.5 mg/kg/week after 2 months if there was no response. The patients were treated at this dose for a total of 6 months, followed by tapering of 0.1 mg/kg/month for 3 months. Relapse was defined as ≥10% increase in SALT score during tapering phase (7–9 months), consistent with prior definitions of recurrence or extension of existing patches.[14] Baseline and follow-up assessments Baseline evaluation included demographic data, disease duration, family and atopy history, and prior treatments. SALT score and patient-reported outcome (PRO) on scalp hair assessment were recorded monthly. Dermatology life quality index (DLQI) and patient health questionnaire (PHQ) scores were assessed at baseline, 6 months, and 9 months. Laboratory monitoring was performed as per standard guidelines. Methodology of alkaline phosphatase activity assessment by immunohistochemistry Scalp biopsies for ALP IHC were obtained at baseline and 6 months from five randomly selected patients per group, based on patient consent and feasibility. Biopsies were processed using standard paraffin-embedded techniques, and ALP activity was assessed after substrate incubation and methyl green counterstaining under inverted microscopy. Study outcomes The primary outcome was the proportion of patients achieving a SALT score ≤20 at 6 months. Secondary outcomes included improvement in PRO score on scalp hair assessment (0–1 or >2-point improvement from baseline 3-point score), SALT90, SALT ≤20 at 3 months, percentage change in SALT from baseline to 6 months, changes in DLQI and PHQ at 6 and 9 months, and adverse events. Statistical analysis Data were analyzed using SPSS v23. Quantitative variables were summarized as mean ± SD or median (interquartile range [IQR]) and compared using Student’s t-test or Mann–Whitney test. Wilcoxon signed-rank test, Chi-square/Fisher’s exact test, and generalized estimating equations assessed longitudinal and intergroup trends. As a pilot study, analyses were exploratory and not powered for hypothesis testing, with descriptive P values reported to highlight trends, effect sizes, and feasibility rather than to arrive at firm conclusions. Results In Group A, four patients were lost to follow-up (three could not be contacted, and one was nonresponder), while two patients discontinued treatment due to adverse effects. In Group B, five discontinued due to adverse effects, and two were lost due to no response. Three patients in each group required dose escalation. Overall, 23 patients completed the 9-month study and all 36 patients were included in intention-to-treat analysis using last observation carried forward. Baseline clinico-demographic and psychological characteristics are shown in Table 1. Table 1Baseline clinico- demographic characteristics and psychological scores of the study populationParametersTofacitinib Group A (n=18)Methotrexate Group B (n=18)P value (two-sided)Age (years±SD)28.3±8.6829.3±8.540.73Gender13: 513: 51.0(male: female)(72.22%: 27.78%)(72.22%: 27.78%)Total duration of illness (years±SD)4.4±5.075.6±5.250.33Age of onset (years±SD)23.8±10.5123.1±9.940.84Initial site of onset (percentage)Scalp16 (88.9%)14 (77.8%)0.8Beard2 (11.1%)3 (16.7%)1Eyebrows0 (0%)1 (5.6%)1Distribution of pattern (percentage)Patchy8 (44.4%)9 (50.00%)0.73Diffuse1 (5.55%)2 (11.11%)1Ophiasis3 (16.67%)4 (22.22%)0.63AT2 (11.11%)2 (11.11%)1AU4 (22.22%)1 (5.55%)0.33Other sites involved besides scalp (percentage)16 (88.9%)11 (61.1%)0.12Nail Involvement (percentage)4 (22.2%)4 (22.2%)1.0Precipitating factors (percentage)2 (11.1%)2 (11.1%)1.0Past history of AA (percentage)7 (38.9%)10 (55.6%)0.31Comorbidities (percentage)4 (22.2%)3 (16.7%)0.69Treatment taken in the past (percentage)15 (83.3%)16 (88.9%)1.0Personal history of atopy (percentage)6 (33.3%)7 (38.9%)0.72Family history of atopy (percentage)1 (5.6%)2 (11.1%)1.0Family history of AA (percentage)3 (16.7%)2 (11.1%)1.0SALT score (mean±SD)65.80±25.0352.41±19.490.02Scalp hair assessment PRO score (mean±SD)3.00±0.912.39±0.700.03DLQI (mean±SD)8.78±6.478.44±6.550.83PHQ somatic score (median±IQR)2.0 (1.25–4.0)2.0 (1.0–3.0)0.6PHQ depression score (median±IQR)3.0 (0.0–6.0)3.0 (2.25–5.75)0.66PHQ anxiety score (median±IQR)1.0 (0.0–3.0)0.0 (0.0–0.0)0.02PHQ bulimia nervosa (median±IQR)0.000.00-PHQ anorexia nervosa (median±IQR)0.000.00-AA- Alopecia areata; AT- Alopecia Totalis; AU- Alopecia Universalis; DLQI- Dermatology Life Quality Index; IQR- Interquartile range; PHQ- Patient Health Questionnaire; PRO- Patient-reported outcome; SALT- Severity of alopecia tool score; SD- Standard deviation Baseline clinico- demographic characteristics and psychological scores of the study population AA- Alopecia areata; AT- Alopecia Totalis; AU- Alopecia Universalis; DLQI- Dermatology Life Quality Index; IQR- Interquartile range; PHQ- Patient Health Questionnaire; PRO- Patient-reported outcome; SALT- Severity of alopecia tool score; SD- Standard deviation Primary outcome A SALT score of ≤20 at 6 months was achieved by 50% of patients (9/18) in Group A and 33.33% (6/18) in Group B (P = 0.31). Trend analysis showed greater SALT improvement with tofacitinib (P = 0.004) [Figure 1]. Analyses were exploratory. Representative clinical photographs are shown in Figures 2 and 3. Line diagram depicting trends in severity of alopecia tool (SALT) score during the study duration Photographic representation of the patient on tofacitinib at baseline and 6 months Photographic representation of the patient on methotrexate at baseline and 6 months Secondary outcomes At baseline, 11 patients in Group A and 5 in Group B had scalp hair assessment PRO score ≥3. At 6 months, 72.2% (8/11) of Group A patients and none in Group B achieved a score of 0–1 or showed a ≥2-point improvement from baseline. Trend analysis of PRO scores over time also favored tofacitinib (P < 0.001) [Supplementary Figure 2]. SALT90 was achieved at 6 months by 33.3% (6/18) of patients in Group A and 11.1% (2/18) in Group B (P = 0.10), representing a numerical trend. At 3 months, SALT ≤20 was observed in 22.2% (4/18) of Group A and 11.1% (2/18) of Group B patients (P = 0.37). The mean percentage change in SALT score differed significantly between groups at the third, fourth and fifth months. The maximum improvement occurred at 6 months, with Group A showing a change of −60.24 ± 40.24% and Group B showing a change of −38.16 ± 38.92% (P = 0.07), indicating a greater magnitude of improvement with tofacitinib, although this difference was exploratory. Change in Dermatology Life Quality Index and Patient Health Questionnaire scores at 6 months and 9 months from baseline In Group A, the mean DLQI score significantly decreased from 8.7 ± 6.47 at baseline to 3.7 ± 5.09 at 6 months but increased to 4.9 ± 4.33 at 9 months (P = 0.007). Group B also showed a significant reduction in DLQI from 8.4 ± 6.55 at baseline to 4.3 ± 5.40 at 6 months, with a subsequent increase to 5.8 ± 6.45 at 9 months (P = 0.007). Intergroup differences in DLQI were not significant at 6 or 9 months. PHQ scores did not differ significantly over time, and no cases of bulimia nervosa or anorexia nervosa were observed [Supplementary Figures 3–6]. Adverse effects The common adverse events in Group A were dyslipidemia (16.6%), scalp folliculitis (11.1%), leukopenia (5.5%), and renal stones (5.5%), whereas patients in Group B experienced transaminitis (16.6%), scalp folliculitis (5.5%), varicella infection (5.5%) and fever with cytopenias (5.5%). Adverse effects are tabulated in Supplementary Tables 1 and 2. Supplementary Table 1Adverse events in both groups over the study periodGroup A (7/18)Group B (6/18)Infections (number; percentage)Infections (number; percentage)Scalp folliculitis (2; 11.1%)Scalp folliculitis (1; 5.5%)Varicella infection (1; 5.55%)Biochemical abnormalitiesBiochemical abnormalitiesLipid abnormalities (no; percentage)Transaminitis (3; 16.6%)Total no of patients- (3; 16.6%)Hypercholesterolemia >240 (3; 16.6%)Hypertriglyceridemia >250 (1; 5.5%)LDL >160 (2; 11.1%)CytopeniaCytopeniaLeukopenia <4000 cells/mm3 (1; 5.5%)Fever, leukopenia <4000 cells/mm3 and thrombocytopenia <1,00,000 cells/mm3 (1; 5.5%)OthersRenal stones (1; 5.5%)LDL: Low density lipoprotein Adverse events in both groups over the study period LDL: Low density lipoprotein Supplementary Table 2Classification of adverse events using WHO-UMC causality assessment:Patient IDName of eventDose of DrugTime of onsetCausalityDrug discontinuation1Renal stonesTofacitinib 5mg BD5 monthsPossibleYes4Scalp folliculitisTofacitinib 5mg BD2 monthsPossibleNo10Scalp folliculitisTofacitinib 5mg BD3 monthsPossibleNo15LeukopeniaTofacitinib 5 mg BD6 monthsProbableYes2,3,5DyslipidemiaTofacitinib 5mg BD (2 patients), Tofacitinib 10 mg BD (1 patient)4 monthsProbableManaged with dietary modifications and low-dose statins21TransaminitisMethotrexate 15 mg/week3 monthsProbableYes22TransaminitisMethotrexate 25 mg/week2 monthsProbableYes23Varicella infectionMethotrexate 15 mg/week5 monthsPossibleYes26TransaminitisMethotrexate 15 mg/week1.5 monthsProbableYes36Scalp folliculitisMethotrexate 15 mg/week2 monthsPossibleNo37Fever and cytopeniaMethotrexate 15 mg/week2 monthsPossibleYesBD- Twice a day; WHO-UMC-World Health Organisation- Uppsala Monitoring Centre Classification of adverse events using WHO-UMC causality assessment: BD- Twice a day; WHO-UMC-World Health Organisation- Uppsala Monitoring Centre Relapse In Group A, 50% (9/18) of patients experienced relapse during the 3-month follow-up period, compared to 33.3% (6/18) in Group B, with no statistically significant difference (P = 0.31), highlighting the relapsing nature. ALP activity Ten scalp biopsies were assessed for ALP activity. At baseline, 80% were ALP negative. By 6 months, four patients converted to ALP positive, two remained positive, and four remained negative. Eight patients achieved >50% SALT improvement, while two showed limited response. Shorter disease duration (<5 years) was associated with better outcomes, and ALP activity showed a moderate correlation with SALT improvement (r = 0.52, P = 0.08). These preliminary findings require validation in larger studies [Supplementary Table 3]. Supplementary Table 3Correlation between ALP activity, SALT score, and disease durationPatient IDTotal Duration of diseaseCurrent episodeSALT score at baselineSALT score at 6 months>50% improvement in SALT score at 6 months (Responders)ALP activity at baselineALP activity at 6 months202 years2 years41.222.6NoNegativeNegative235-6 years8 months405.8YesNegativeNegative246 months6 months49.026.4YesPositiveNegative253-4 years7 months417.8YesNegativeNegative275-6 years6-7 months43.49.6YesNegativePositive2914-15 years1 year5632.7NoNegativeNegative14 years6 months46.81.8YesNegativePositive420 years10 years10030.2YesNegativePositive52 years8 months1003.6YesPositivePositive64 years7 months54.69.6YesNegativeNegativeALP- Alkaline phosphatase. SALT- Severity of alopecia tool score Correlation between ALP activity, SALT score, and disease duration ALP- Alkaline phosphatase. SALT- Severity of alopecia tool score Discussion This study compared the efficacy and safety of oral tofacitinib and methotrexate monotherapy for treating moderate-to-severe AA, highlighting the growing interest in JAK–STAT inhibitors and methotrexate as a standalone treatment. The response rates observed with tofacitinib align with previous studies, with 22.2% of patients achieving a partial response and 61.1% achieving a good or complete response.[7915] In contrast, methotrexate demonstrated lower efficacy than reported in earlier studies, with partial and good/complete responses in 27.7% and 33.3% of patients, respectively, possibly reflecting the shorter treatment duration, as longer courses are often associated with improved outcomes.[916171819] Relapse during the tapering phase occurred in 50% of patients treated with tofacitinib and 33.3% of those receiving methotrexate, consistent with the literature.[789] Baseline DLQI scores (8.61 ± 6.41) indicated a moderate impact on quality of life, higher than pooled estimates of 6.3 from meta-analyses, likely due to inclusion of more severe disease. Quality-of-life and psychological scores improved with hair regrowth but worsened during treatment tapering, aligning with relapse. In the tofacitinib group, 38.8% experienced adverse events, such as dyslipidemia, scalp folliculitis, leukopenia, and renal stones, consistent with previous studies, while 33.3% in methotrexate group developed adverse effects such as transaminitis, scalp folliculitis, varicella infection, and cytopenias.[7891020] ALP activity, a proposed marker of hair regrowth, showed inconsistent expression but was more frequently positive in patients with shorter disease duration and better response, suggesting a possible association requiring validation in larger studies.[820] Strengths and limitations This study provides comparative data on tofacitinib and methotrexate, strengthened by randomization and systematic assessment, but is limited by lack of formal sample size calculation, small sample size, open-label design, lack of stratification, and baseline imbalances that may affect achievable improvement and comparative interpretation. Conclusion As a pilot randomized controlled trial, our study provides preliminary evidence that tofacitinib may offer superior response compared with methotrexate in moderate-to-severe AA. However, the results should be extrapolated carefully, given the small sample size and exploratory nature of the study. Future multicenter trials with larger sample sizes are needed to validate these results and further investigate ALP activity in AA pathogenesis. Authors’ contributions We confirm that all authors have read and approved the manuscript for submission. All authors meet authorship criteria, and the manuscript represents honest work. Data availability statement Data are available from the corresponding author on reasonable request. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence (AI) The preparation of this manuscript was carried out entirely by the authors without the use of artificial intelligence technologies. CONSORT study flow diagram. *Intention to treat group- who had at least one follow-up visit Line diagram depicting trends in scalp hair assessment patient-related outcome (PRO) score during the study period Line diagram depicting trends in dermatology life quality index (DLQI) score during the study period Line diagram depicting trends in patient health questionnaire (PHQ) somatic score during the study period Line diagram depicting trends in PHQ depression score during the study period Line diagram depicting trends in PHQ anxiety score during the study period